2025
A road map for uniform, comprehensive long-term follow-up after curative therapy for sickle cell disease
Shenoy S, Kanter J, Kassim A, Fitzhugh C, Stenger E, Bhatia M, Pecker L, Krishnamurti L, King A. A road map for uniform, comprehensive long-term follow-up after curative therapy for sickle cell disease. Blood Advances 2025, 9: 3090-3103. PMID: 39993235, DOI: 10.1182/bloodadvances.2024013953.Peer-Reviewed Original ResearchNew Frontier, New Challenges—Recognizing and Managing Adverse Effects of Antiamyloid Therapies
Rech M, Aggarwal N, Hwang U. New Frontier, New Challenges—Recognizing and Managing Adverse Effects of Antiamyloid Therapies. JAMA Internal Medicine 2025, 185 PMID: 40549376, DOI: 10.1001/jamainternmed.2025.2242.Peer-Reviewed Original ResearchRole of PLK4 inhibition in cancer therapy
Banik K, Hayman T. Role of PLK4 inhibition in cancer therapy. Cancer And Metastasis Reviews 2025, 44: 55. PMID: 40512236, DOI: 10.1007/s10555-025-10271-5.Peer-Reviewed Original ResearchConceptsAssociated with more advanced diseaseCancer therapyAssociated with tumor progressionMore advanced diseasePolo-like kinase 4PLK4 overexpressionMultiple cancer typesAdvanced diseaseTherapeutic resistanceClinical outcomesTumor progressionSmall molecule inhibitorsHuman tumorsCancer typesDNA-damaging agentsSerine-threonine kinaseCancerOncogenic processesTherapeutic gainTherapeutic targetPolo-like kinase 4 inhibitorPLK4 inhibitionKinase 4Genomic instabilityTherapySafety overview and management of inavolisib alone and in combination therapies in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer (GO39374)
Gambardella V, Accordino M, Bedard P, Cervantes A, Hamilton E, Italiano A, Kalinsky K, Krop I, Oliveira M, Saura C, Schmid P, Turner N, Varga A, Fernandez-Saranillo A, Jin Y, Royer-Joo S, Peters U, Shankar N, Schutzman J, Juric D, Jhaveri K. Safety overview and management of inavolisib alone and in combination therapies in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer (GO39374). ESMO Open 2025, 10: 105303. PMID: 40513140, PMCID: PMC12205636, DOI: 10.1016/j.esmoop.2025.105303.Peer-Reviewed Original ResearchHER2-negative advanced breast cancerAdvanced breast cancerAdverse eventsCombination therapyPIK3CA-mutationsBreast cancerHormone receptor (HR)-positiveDiscontinued study treatmentBreast cancer therapyLong-term toleranceDose reductions/interruptionsAny-gradeData cutoffDose modificationTolerability profileHR-positiveProgressive diseaseStudy treatmentMetformin treatmentCancer therapyNo treatmentPatientsRisk factorsTherapyHyperglycemiaRole of Chimeric Antigen Receptor–Expressing Cell Therapy in Immune-Mediated Kidney Diseases: A Review
Peng J, Zhang Y, Wang J, Zhang H, Schett G. Role of Chimeric Antigen Receptor–Expressing Cell Therapy in Immune-Mediated Kidney Diseases: A Review. American Journal Of Kidney Diseases 2025 PMID: 40484342, DOI: 10.1053/j.ajkd.2025.04.012.Peer-Reviewed Original ResearchImmune-mediated kidney diseasesB-cell depletionB cellsKidney diseaseCell therapyPlasma cellsTreatment of immune-mediated kidney diseasesB-cell-depleting monoclonal antibodyB-cell targeted therapiesComplete B-cell depletionAutoantibody-producing plasma cellsDeplete plasma cellsMonoclonal antibodiesAntigen-presenting cellsAdaptive immune responsesImmune-mediatedSelf-antigensT cellsImmune cellsImmune responseTherapyInfiltrated tissuesDiseaseAntibodiesCellsSpatial transcriptomic analysis of immune checkpoint blockade response in triple negative breast cancers with tertiary lymphoid structures
Mebane R, Noel T, Ing N, Gouin K, Shah A, Zitser D, Martinez A, Gupta G, Demaria S, Galluzzi L, Ho A, McArthur H, Shiao S, Knott S. Spatial transcriptomic analysis of immune checkpoint blockade response in triple negative breast cancers with tertiary lymphoid structures. IScience 2025, 28: 112808. PMID: 40599321, PMCID: PMC12209978, DOI: 10.1016/j.isci.2025.112808.Peer-Reviewed Original ResearchTertiary lymphoid structuresLymphoid structuresRadiation therapyImmunotherapy responseImmune checkpoint blockade responseTriple negative breast cancerCancer immunotherapy responseNegative breast cancerCancer cell removalTumor bedBlockade responseMalignant cellsBreast tumorsImmune activationMacrophage infiltrationPembrolizumabBreast cancerLongitudinal biopsiesSpatial transcriptomic analysisTumorTherapyCancerInfiltrationCell removalImmunotherapyUse of targeted therapy in patients with advanced non-small cell lung cancer in response to broad genomic profiling.
Wang X, Long J, Rothen J, Huang S, Soulos P, Robinson T, Presley C, Goldberg S, Mamtani R, Ma S, Wang S, Kunst N, Dinan M, Gross C. Use of targeted therapy in patients with advanced non-small cell lung cancer in response to broad genomic profiling. Journal Of Clinical Oncology 2025, 43: 11155-11155. DOI: 10.1200/jco.2025.43.16_suppl.11155.Peer-Reviewed Original ResearchAdvanced non-small cell lung cancerNon-small cell lung cancerCell lung cancerTargeted therapyLung cancerTargetable alterationsGenomic profilingUsefulness of targeted therapyUS cancer clinicsFirst-line treatmentCohort of patientsClinico-genomic databaseNCCN GuidelinesIdentified patientsPatient populationFDA approvalTreatment selectionPatientsCancer clinicClinical guidelinesTherapyCancerLimited dataTT useFDA approval statusEvolving trends in Latin American oncology clinical trial sites.
Paredes R, Karol A, Markus A, Argulian A, Omori R, Fujiwara Y, Joshi H, Doroshow D, Galsky M. Evolving trends in Latin American oncology clinical trial sites. Journal Of Clinical Oncology 2025, 43 DOI: 10.1200/jco.2025.43.16_suppl.e23155.Peer-Reviewed Original ResearchPlacebo-controlled designHispanic participantsParticipant recruitmentParticipant enrollmentWorld Bank criteriaTrial sitesParticipant dataStudy evaluated trendsAntibody-drug conjugatesHealthcare infrastructureMulti-arm designPhase 3 oncology trialsHormone therapyBiologic therapyClinical trial sitesTargeted therapyPARP inhibitorsLatin America countriesTrial initiationTherapyParticipantsCancer typesSite proportionsClinical researchOncology trialsChallenging IVC filter removal complicated by strut penetration and prolonged dwell
Kostiuk V, Rodriguez P, Tonnessen B, Lozada J, Guzman R, Chaar C. Challenging IVC filter removal complicated by strut penetration and prolonged dwell. Journal Of Vascular Surgery Cases And Innovative Techniques 2025, 101894. DOI: 10.1016/j.jvscit.2025.101894.Peer-Reviewed Original ResearchInferior vena cavaInferior vena cava filter removalFilter removalAnticoagulant therapyStrut penetrationProximal right common iliac arteryPlacement of inferior vena cavaRight common iliac arteryFilter strut penetrationPulmonary embolism preventionInferior vena cava wallCommon iliac arteryL4 vertebral bodyEmbolism preventionFrequent complicationVena cavaFilter retrievalIliac arteryPatient's symptomsSurrounding organsVertebral bodyTemporary placementPatientsAnticoagulationTherapyAdvance care planning documentation prior to end-of-life systemic therapy: A single institution retrospective review.
Xiang J, Wiese B, Patlovich K, Taylor J, Adelson K, Ratan R. Advance care planning documentation prior to end-of-life systemic therapy: A single institution retrospective review. Journal Of Clinical Oncology 2025, 43 DOI: 10.1200/jco.2025.43.16_suppl.e24031.Peer-Reviewed Original ResearchSystemic anticancer therapyMonths of lifeTargeted therapyDose of treatmentAdvance care planning notesFinal treatmentAdvance care planningEnd-of-lifeHigher risk of mortalityDocumented discussionAssociated with decreased quality of lifeRisk of mortalityAssociated with decreased qualityMetastatic diseaseHigh healthcare useInpatient settingSolid tumorsRetrospective studyMD AndersonCellular therapyMedical oncologistsAnticancer therapyImmunotherapyTherapyPatientsA Case of Persistent, Delayed Multisystem Toxicities After Anti-PD-1 Therapy
Goodman R, Burnette H, Johnson D. A Case of Persistent, Delayed Multisystem Toxicities After Anti-PD-1 Therapy. 2025, 449-454. DOI: 10.1007/978-3-031-83533-9_56.Peer-Reviewed Original ResearchClinical factors influencing retreatment with anti-PD-(L)1 therapies after treatment in early-stage cancers: a modified Delphi consensus study
Pusztai L, Sondak V, Aguiar-Ibáñez R, Cappuzzo F, Chouaid C, Elder C, Hirasawa Y, Ishida M, Jones R, Lee S, Mizuno R, Nagata M, Okonji D, Parente P, Shah B, Sun A, Ferreira D, Spiteri C, Lauer A, Kaliasethi A, Kao C, Kothari S, McKendrick J. Clinical factors influencing retreatment with anti-PD-(L)1 therapies after treatment in early-stage cancers: a modified Delphi consensus study. Journal For ImmunoTherapy Of Cancer 2025, 13: e011184. PMID: 40425232, PMCID: PMC12107590, DOI: 10.1136/jitc-2024-011184.Peer-Reviewed Original ResearchConceptsAnti-PD-(L)1 treatmentAnti-PD-(L)1Anti-PD-(L)1 therapyEarly-stage cancerAnti-PD-(L)1 agentsRetreatment of patientsAnti-programmed deathTreating early-stage cancersAdjuvant settingMetastatic settingNeoadjuvant settingRetreatment patientsClinical expertsAdjuvant treatmentEarly-stage treatmentRetreatment decisionsClinical factorsRepeated treatmentTherapyCancer typesCancerPatient responseClinical practicePatientsRelapseUpdates on radiotherapy-immunotherapy combinations: Proceedings of 8th Annual ImmunoRad Conference
Talebi F, Gregucci F, Ahmed J, Chetrit N, Brown B, Chan T, Chand D, Constanzo J, Demaria S, Gabrilovich D, Golden E, Godkin A, Guha C, Gupta G, Hasan A, Herrera F, Kaufman H, Li D, Melcher A, McDonald S, Merghoub T, Monjazeb A, Paris S, Pitroda S, Sadanandam A, Schaue D, Santambrogio L, Szapary P, Sage J, Welsh J, Wilkins A, Young K, Wennerberg E, Zitvogel L, Galluzzi L, Deutsch E, Formenti S. Updates on radiotherapy-immunotherapy combinations: Proceedings of 8th Annual ImmunoRad Conference. OncoImmunology 2025, 14: 2507856. PMID: 40401900, PMCID: PMC12101595, DOI: 10.1080/2162402x.2025.2507856.Peer-Reviewed Original ResearchAcquired angio-oedema as a mimicker of drug allergy
Liao J, Mathew M, Elmansy L, Hsu F, Belmont A. Acquired angio-oedema as a mimicker of drug allergy. BMJ Case Reports 2025, 18: e265525. PMID: 40389294, DOI: 10.1136/bcr-2025-265525.Peer-Reviewed Original ResearchConceptsAcquired angio-oedemaAngio-oedemaSplenic marginal zone lymphomaBradykinin-mediated diseaseSevere angio-oedemaMarginal zone lymphomaLocal anaesthetic allergyDrug allergy testingDental proceduresAcute therapyCase reportClinical historyDrug allergyAllergy centresAllergy testingClinical pearlsClinical diagnosisEmergency departmentMultiple physiciansDiagnosisAllergyLymphomaTherapyPatientsAetiologyPractical Guide on the Use of Induction Immunosuppression in Heart Transplantation.
Nikolova A, Bellumkonda L, Bhardwaj A, Fida N, Holzhauser L, Umapathi P, De Marco T, Contreras J. Practical Guide on the Use of Induction Immunosuppression in Heart Transplantation. Circulation Heart Failure 2025, e012382. PMID: 40371476, DOI: 10.1161/circheartfailure.124.012382.Peer-Reviewed Original ResearchInduction immunosuppressionHeart transplantationImpact of induction immunosuppressionHepatitis C positivityRenal protective strategiesRisk stratification modelAt-risk patientsInduction therapyInduction regimensCirculatory death donorsMalignant complicationsMechanical circulatory devicesPerioperative periodImmunomodulatory effectsRecipient riskImmunosuppressionDeath donorsStratification modelTransplantationTherapyPatientsCirculatory devicesAt-riskInductionTreatment Patterns and Real-World Outcomes of Molecular Subgroups in Patients With AML Receiving Frontline Venetoclax-Based Therapy.
Lachowiez C, Barcellos A, Zettler C, Belli A, Fernandes L, Hansen E, Wang C, Owusu H, Zeidan A, Stein E, Swords R. Treatment Patterns and Real-World Outcomes of Molecular Subgroups in Patients With AML Receiving Frontline Venetoclax-Based Therapy. JCO Oncology Practice 2025, op2400983. PMID: 40340477, DOI: 10.1200/op-24-00983.Peer-Reviewed Original ResearchVEN-based therapyTreatment patternsTime to next treatmentVenetoclax-based therapyVIALE-A trialEvent-free survivalLow-intensity regimensKaplan-Meier methodOutcomes of patientsInduction chemotherapyDiagnosed AMLIntensive chemotherapySecond-lineMutation statusFirst-lineInvestigational therapiesIndex dateMolecular subgroupsFLT3</i>-ITDNext treatmentDose informationTherapyAMLPatientsNovel treatmentThe treatment of cutaneous immune-related adverse events from immune checkpoint inhibitors with biologic therapy: A single-institution retrospective study at a tertiary care cancer center
Greenberg A, Valido K, Vesely M, Leventhal J. The treatment of cutaneous immune-related adverse events from immune checkpoint inhibitors with biologic therapy: A single-institution retrospective study at a tertiary care cancer center. Journal Of The American Academy Of Dermatology 2025 PMID: 40345549, DOI: 10.1016/j.jaad.2025.04.075.Peer-Reviewed Original Research2024 American College of Rheumatology (ACR) Guideline for the Screening, Treatment, and Management of Lupus Nephritis
Sammaritano L, Askanase A, Bermas B, Dall'Era M, Duarte‐García A, Hiraki L, Rovin B, Son M, Alvarado A, Aranow C, Barnado A, Broder A, Brunner H, Chowdhary V, Contreras G, Felix C, Ferucci E, Gibson K, Hersh A, Izmirly P, Kalunian K, Kamen D, Rollins B, Smith B, Thomas A, Timlin H, Wallace D, Ward M, Azzam M, Bartels C, Cunha J, DeQuattro K, Fava A, Figueroa‐Parra G, Garg S, Greco J, Cuéllar‐Gutiérrez M, Iyer P, Johannemann A, Jorge A, Kasturi S, Kawtharany H, Khawandi J, Kirou K, Legge A, Liang K, Lockwood M, Sanchez‐Rodriguez A, Turgunbaev M, Williams J, Turner A, Mustafa R. 2024 American College of Rheumatology (ACR) Guideline for the Screening, Treatment, and Management of Lupus Nephritis. Arthritis & Rheumatology 2025 PMID: 40331662, DOI: 10.1002/art.43212.Peer-Reviewed Original ResearchManagement of lupus nephritisLupus nephritisAmerican College of Rheumatology (ACRTreatment decisionsLupus nephritis therapyBest practice statementsQuality of evidencePulse glucocorticoidsGlucocorticoid taperingImmunosuppressive agentsRenal responseRecommendations AssessmentNephritisAmerican CollegeVoting panelClinical situationsGRADE recommendationsIndividual patientsTherapyPractice statementsEvidence-basedPICO questionClinical questionsPICO formatSystematic literature reviewLetter to the Editor: Effect of Nicotine Replacement Therapy on Perioperative Pain Management and Opioid Requirement in Abstinent Tobacco Smokers Undergoing Spinal Fusion: A Double-Blind Randomized Controlled Trial.
Costa G, De Aquino J. Letter to the Editor: Effect of Nicotine Replacement Therapy on Perioperative Pain Management and Opioid Requirement in Abstinent Tobacco Smokers Undergoing Spinal Fusion: A Double-Blind Randomized Controlled Trial. Journal Of Neurosurgical Anesthesiology 2025 PMID: 40325556, DOI: 10.1097/ana.0000000000001041.Peer-Reviewed Original ResearchAccelerated Aging in Cancer and Cancer Treatment: Current Status of Biomarkers
Abraham S, Parekh J, Lee S, Afrin H, Rozenblit M, Blenman K, Perry R, Ferrucci L, Liu J, Irwin M, Lustberg M. Accelerated Aging in Cancer and Cancer Treatment: Current Status of Biomarkers. Cancer Medicine 2025, 14: e70929. PMID: 40322791, PMCID: PMC12051034, DOI: 10.1002/cam4.70929.Peer-Reviewed Original ResearchConceptsBiological age of patientsLeukocyte telomere lengthInterleukin-6Treatment-related toxicityAge of patientsTherapy-induced toxicityExpression of p16INK4aPredictors of toxicityStatus of biomarkersMarkers of cellular senescenceRadiation therapyBiological ageCancer patientsCancer therapyFunctional reserveAging biomarkersPhysiological reserveCancer treatmentCancerConfirmatory studiesTherapyClinical practiceFunctional capacityPatientsFunctional status
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply